Abstract: The present invention relates to a heterocyclic compound, a pharmaceutical composition containing the same, a preparation method thereof, and a use thereof as a fibroblast growth factor receptor (FGFR) inhibitor. The compound is a heterocyclic compound as shown in Formula I, or a pharmaceutically acceptable salt, a prodrug, a solvate, a polymorph, an isomer, or a stable isotopic derivative thereof. The present invention further relates to a method of treating or preventing a FGFR-mediated disease, such as cancer, using the compound.

Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).

Abstract: The present invention relates to pyrazole fused-ring derivatives, their preparation methods, and use thereof in medicine. In particular, the present invention relates to a novel derivative represented by formula (I), and a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the same and a method for preparing the same. The present invention also relates to use of the derivatives and the pharmaceutically acceptable salt thereof or the pharmaceutical composition comprising the same in the preparation of therapeutic agents, in particular Bruton tyrosine kinase inhibitors, and preparing a medicament for treating and/or preventing tumors and inflammatory associated diseases. The substituents on formula (I) are defined same as in the specification.

Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).

Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).

Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).

Abstract: To provide a ventilating system and ventilating system control method capable of advancing energy conservation. A controller sets a static pressure setting value based on the airflow of the system as a whole, calculated from the airflow of venturi air valves of fume hoods that are operating, and controls the speed of rotation of a fan based on the static pressure setting value and the static pressure within a main duct. Doing so enables control of the speed of rotation of the fan to be performed while ensuring the airflow of the ventilating system, thus making it possible to prevent wasted motive force of the fan, even when the airflows of each of the venturi air valves are not identical and even when the changes in resistance of the branched duct system relative to the various changes in airflow are not identical, with the result that it is possible to advance energy conservation.

Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R1, R2, R3A, R3B, R4, R5, R6, R7, R8, and X are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, and intermediates are also disclosed.

Abstract: Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.

Abstract: A base station receives (201) OFDMA messages from a plurality of end user platforms that share all used tones within at least one OFDMA symbol. By one approach this base station then uses (202) a fixed starting time to select contiguous samples from received aggregate multi-user signals wherein the fixed starting time is offset from a reference time that comprises a time at which the base station expects to be receiving the signals from all end users. In combination with the time offset approach noted above or in lieu thereof the base station can process (204) selected contiguous samples using fast Fourier transform and then provide (205) phase rotation with respect to those processed samples. When applying phase rotation, by one approach a phase rotation can be applied (401) to the aggregate multi-user signal and, in addition, individual phase rotation can be applied (402) as determined on a user-by-user basis.

Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R1, R2, R3A, R3B, R4, R5, R6, R7, R8, and X are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, and intermediates are also disclosed.

Abstract: A herbicidal composition is provided comprising an aqueous solution of N-phosphonomethylglycine, predominantly in the form of the potassium salt thereof, at a concentration of at least 300 g a.e./l of the composition; and a surfactant component in solution or stable suspension, emulsion, or dispersion in the water, comprising one or more surfactants in a total amount of about 20 to about 300 g/l of the composition, wherein the composition has a viscosity of less than about 250 centipoise at 0° C. or a Gardner color value less than 10.

Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R1, R2, R3A, R3B, R4, R5, R6, R7, R8, and X are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, and intermediates are also disclosed.

Abstract: A wireless transceiver (100) that produces soft decisions for received, block error correction encoded codewords and a confidence indicator signifying a likelihood of errors in the detected data. The wireless transceiver (100) processes block encrypted signals, such as feedback channel messages in a WiMax uplink. Upon receiving a signal, a soft decision is determined for received block encoded codewords. A difference is calculated between a soft decision metric for a most likely detected codeword and a soft decision metric for a next most likely detected codeword. This difference is normalized based upon the total decoder input power received over the received signal (201). The normalized difference is then scaled by a channel dependent factor and is time filtered. The normalized and time filtered confidence indicator output (212) is able to be provided to a wireless network controller to assess the usability of the received data.

Abstract: To provide a ventilating system and ventilating system control method capable of advancing energy conservation. A controller sets a static pressure setting value based on the airflow of the system as a whole, calculated from the airflow of venturi air valves of fume hoods that are operating, and controls the speed of rotation of a fan based on the static pressure setting value and the static pressure within a main duct. Doing so enables control of the speed of rotation of the fan to be performed while ensuring the airflow of the ventilating system, thus making it possible to prevent wasted motive force of the fan, even when the airflows of each of the venturi air valves are not identical and even when the changes in resistance of the branched duct system relative to the various changes in airflow are not identical, with the result that it is possible to advance energy conservation.

Abstract: A method (1700) and apparatus (1801) provide channel estimation with extended bandwidth filters. Antenna (1813) receives a signal such as a pilot signal and detects a bandwidth associated with the pilot signal in a detector (320). One of a plurality of filters (603, 605, 607, and 609) including extended bandwidth filters (311) and a default filter (305) can be selected by a selector (617). If the detector detects activity associated with a wider bandwidth, the filter associated with the wider bandwidth is selected over the presently selected filter. If no activity is detected, the default filter is selected.

Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R1, R2, R3A, R3B, R4, R5, R6, R7, R8, and X are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, and intermediates are also disclosed.

Abstract: A wireless transceiver (100) that produces soft decisions for received, block error correction encoded codewords and a confidence indicator signifying a likelihood of errors in the detected data. The wireless transceiver (100) processes block encrypted signals, such as feedback channel messages in a WiMax uplink. Upon receiving a signal, a soft decision is determined for received block encoded codewords. A difference is calculated between a soft decision metric for a most likely detected codeword and a soft decision metric for a next most likely detected codeword. This difference is normalized based upon the total decoder input power received over the received signal (201). The normalized difference is then scaled by a channel dependent factor and is time filtered. The normalized and time filtered confidence indicator output (212) is able to be provided to a wireless network controller to assess the usability of the received data.

Abstract: A base station receives (201) OFDMA messages from a plurality of end user platforms that share all used tones within at least one OFDMA symbol. By one approach this base station then uses (202) a fixed starting time to select contiguous samples from received aggregate multi-user signals wherein the fixed starting time is offset from a reference time that comprises a time at which the base station expects to be receiving the signals from all end users. In combination with the time offset approach noted above or in lieu thereof the base station can process (204) selected contiguous samples using fast Fourier transform and then provide (205) phase rotation with respect to those processed samples. When applying phase rotation, by one approach a phase rotation can be applied (401) to the aggregate multi-user signal and, in addition, individual phase rotation can be applied (402) as determined on a user-by-user basis.